<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Jazz Pharmaceuticals Plc — News on 6ix</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc</link>
<description>Latest news and press releases for Jazz Pharmaceuticals Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 27 May 2026 21:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/jazz-pharmaceuticals-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683587fd78dffbe2df0fe9b9.webp</url>
<title>Jazz Pharmaceuticals Plc</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc</link>
</image>
<item>
<title>Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/phase-3-herizon-gea-01-results-published-in-the-new-england-journal-of-medicine-show-durable-and-consistent-survival-benefit-with-ziiherar-zanidatamab-hrii-combinations-in-first-line-her2-locally-advanced-or-metastatic-gea</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/phase-3-herizon-gea-01-results-published-in-the-new-england-journal-of-medicine-show-durable-and-consistent-survival-benefit-with-ziiherar-zanidatamab-hrii-combinations-in-first-line-her2-locally-advanced-or-metastatic-gea</guid>
<pubDate>Wed, 27 May 2026 21:00:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing the efficacy and safety profile of Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with and without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach,</description>
</item>
<item>
<title>Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-first-quarter-2026-financial-results</guid>
<pubDate>Tue, 05 May 2026 20:05:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2026 (1Q26).</description>
</item>
<item>
<title>ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/alx-oncology-announces-that-cd47-biomarker-data-from-clinical-trial-evaluating-evorpacept-zanidatamab-combination-in-advanced-breast-cancer-will-be-presented-at-esmo-breast-cancer-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/alx-oncology-announces-that-cd47-biomarker-data-from-clinical-trial-evaluating-evorpacept-zanidatamab-combination-in-advanced-breast-cancer-will-be-presented-at-esmo-breast-cancer-2026-1</guid>
<pubDate>Thu, 30 Apr 2026 12:00:00 GMT</pubDate>
<description>- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz P</description>
</item>
<item>
<title>Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-supplemental-biologics-license-application-for-ziiherar-zanidatamab-hrii-combinations-in-first-line-her2-locally-advanced-or-metastatic-gea</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-supplemental-biologics-license-application-for-ziiherar-zanidatamab-hrii-combinations-in-first-line-her2-locally-advanced-or-metastatic-gea</guid>
<pubDate>Mon, 27 Apr 2026 11:45:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) containing combinations for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or gastroesophageal adenocarcinoma (GEA). The FDA has set a PDUFA target action date</description>
</item>
<item>
<title>HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/healthcare-royalty-announces-royalty-monetization-agreement-for-modeysor-commercial-royalties-2</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/healthcare-royalty-announces-royalty-monetization-agreement-for-modeysor-commercial-royalties-2</guid>
<pubDate>Wed, 22 Apr 2026 19:26:00 GMT</pubDate>
<description>STAMFORD, Conn., April 22, 2026--HealthCare Royalty ("HCRx") today announced it has entered into a royalty monetization agreement with the Advisory Group representing the former Oncoceutics Inc. securityholders for an undisclosed percentage of royalties on Modeyso® (dordaviprone) commercial sales.</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-report-first-quarter-financial-results-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-report-first-quarter-financial-results-on-may-5-2026</guid>
<pubDate>Tue, 21 Apr 2026 20:15:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-data-at-asco-2026-highlighting-advancements-for-ziiherar-zanidatamab-hrii-in-gastroesophageal-adenocarcinoma-and-zepzelcar-lurbinectedin</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-data-at-asco-2026-highlighting-advancements-for-ziiherar-zanidatamab-hrii-in-gastroesophageal-adenocarcinoma-and-zepzelcar-lurbinectedin</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present three rapid oral and seven poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29-June 2, 2026, in Chicago. The data reflect Jazz's continued momentum in oncology and the Company's focus on advancing treatment approaches in difficult-to-treat cancers through late-stage clinical research, real-world evidence and ongoing pipeline innovati</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-research-on-epidiolexr-cannabidiol-and-xywavr-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-at-the-2026-american-academy-of-neurology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-research-on-epidiolexr-cannabidiol-and-xywavr-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-at-the-2026-american-academy-of-neurology-annual-meeting</guid>
<pubDate>Thu, 09 Apr 2026 11:45:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago.</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-participate-in-needham-virtual-healthcare-conference-3</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-participate-in-needham-virtual-healthcare-conference-3</guid>
<pubDate>Wed, 01 Apr 2026 20:15:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 15, 2026, at 8:45 a.m. PT / 11:45 a.m. ET / 4:45 p.m. IST.</description>
</item>
<item>
<title>American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/american-nutrition-association-announces-initiative-with-jazz-pharmaceuticals-to-advance-evidence-based-sodium-reduction-and-cardiovascular-health-education</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/american-nutrition-association-announces-initiative-with-jazz-pharmaceuticals-to-advance-evidence-based-sodium-reduction-and-cardiovascular-health-education</guid>
<pubDate>Tue, 24 Mar 2026 17:49:00 GMT</pubDate>
<description>The American Nutrition Association (ANA) today announced its initiative with Jazz Pharmaceuticals to provide evidence-based nutritional education to support people living with narcolepsy or idiopathic hypersomnia (IH) sleep disorders associated with elevated cardiovascular (CV) and cardiometabolic (CM) risk, which make targeted, proactive nutrition even more critical. Together, they aim to translate the latest nutrition science into actionable, patient-centered guidance for people living with th</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-compelling-clinical-and-pre-clinical-data-advancing-oncology-research-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-to-present-compelling-clinical-and-pre-clinical-data-advancing-oncology-research-at-aacr-2026</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones,</description>
</item>
<item>
<title>Rylaze (Jazz Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/rylaze-jazz-pharmaceuticals-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/rylaze-jazz-pharmaceuticals-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 11:08:00 GMT</pubDate>
<description>Opportunities in the Rylaze market include growth from investments in pediatric oncology drugs, demand for personalized and safer leukemia therapies, and the expansion of cancer centers. Advancements in recombinant formulations and flexible dosing enhance treatment adherence, while rising investment in novel biologics further drives market growth.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Rylaze Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added</description>
</item>
<item>
<title>Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2025-financial-results-and-provides-2026-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2025-financial-results-and-provides-2026-financial-guidance</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026.</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-upcoming-investor-211500132</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-upcoming-investor-211500132</guid>
<pubDate>Tue, 17 Feb 2026 21:15:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences:</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-report-fourth-quarter-211500096</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-report-fourth-quarter-211500096</guid>
<pubDate>Tue, 10 Feb 2026 21:15:00 GMT</pubDate>
<description>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results and provide a business and financial update.</description>
</item>
<item>
<title>Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/boehringer-ingelheim-announces-clinical-collaboration-with-jazz-pharmaceuticals-to-advance-her2-targeted-therapy-in-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/boehringer-ingelheim-announces-clinical-collaboration-with-jazz-pharmaceuticals-to-advance-her2-targeted-therapy-in-breast-cancer</guid>
<pubDate>Mon, 12 Jan 2026 12:05:00 GMT</pubDate>
<description>Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (Nasdaq: JAZZ) on the exploration of a novel combination therapy for patients with HER2-positive breast cancer. As part of this collaboration, the partners will initiate a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial, evaluating the c</description>
</item>
<item>
<title>Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-appoints-thomas-riga-chief-business-officer-2026-01-08</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-appoints-thomas-riga-chief-business-officer-2026-01-08</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and</description>
</item>
<item>
<title>Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/ziiherar-zanidatamab-hrii-combinations-achieve-unprecedented-results-first-line-1</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/ziiherar-zanidatamab-hrii-combinations-achieve-unprecedented-results-first-line-1</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Positive Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Participate in Upcoming Investor Events</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-upcoming-investor-events-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-participate-upcoming-investor-events-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor</description>
</item>
<item>
<title>Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting</title>
<link>https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-present-extensive-new-data-and-real-world-evidence-highlighting</link>
<guid isPermaLink="true">https://6ix.com/company/jazz-pharmaceuticals-plc/news/jazz-pharmaceuticals-present-extensive-new-data-and-real-world-evidence-highlighting</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements</description>
</item>
</channel>
</rss>